HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- In age of misinformation, cancer care community seeks new ways to improve communication Ryan Lawrence
-
- ‘Like’ it or not: The dos and don’ts of social media for oncologists Ryan Lawrence
- Now more than ever in medicine, one must adapt to survive Nicholas J. Petrelli, MD, FACS
- Artificial intelligence-derived biomarker predicts ADT benefit in prostate cancer subset Mark Leiser
- Blood test plus risk model may help improve selection for lung cancer screening Jennifer R. Southall
- Enfortumab vedotin active in cisplatin-ineligible muscle-invasive bladder cancer Mark Leiser
- Gene therapy shows promise as potential cure for sickle cell disease Jennifer R. Southall
- Immune cell parameters linked to therapeutic efficacy in advanced renal cell carcinoma Devin McLaughlin
- Lenvatinib combination improves outcomes in advanced hepatocellular carcinoma Jennifer R. Southall
-
- Multimodal AI model superior to standard for prediction of key prostate cancer endpoints Devin McLaughlin
- Nivolumab regimen misses PFS endpoint but shows promise in metastatic colorectal cancer Jennifer R. Southall
- Olaparib regimen benefits men with metastatic castration-resistant prostate cancer Devin McLaughlin
- Patients with cancer have no added adverse reactions to COVID-19 vaccines Jennifer R. Southall
- Septic shock linked to high mortality rates among patients with hematologic malignancies Jennifer R. Southall
- ASH recognizes Choosing Wisely champions
- Blood cancer center names inaugural director
- Cancer consortium announces new leadership
-
- Johns Hopkins appoints genetic medicine director